Evidence map›Paper›PMID 26034111›Full record

ArticleHaematologica2015

Health-related quality of life in patients with multiple myeloma--does it matter?

Ann Kristin Kvam, Anders Waage

Open access · goldAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Assessment tools for peripheral neuropathy in multiple myeloma.The Korean journal of internal medicine · 2026
    Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Observational
  9. Quality of Life Among Polish Patients with Multiple Myeloma: A Cross-Sectional Study.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ann Kristin KvamDepartment of Hematology, Akershus University Hospital, Lørenskog, Norwegian University of Science and Technology, Trondheim, Norway.
Anders WaageDepartment of Hematology, Department of Medicine, St Olavs University Hopsital, and Jebsen Center for Myeloma Research, Institute of Cancer Research and Moleclar Medicine, Norwegian University of Science and Technology, Trondheim, Norway anders.waage@ntnu.no.
Akershus University Hospital · NONorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Health StatusQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMultiple Myeloma

Identifiers

PMID26034111
PMCPMC4450614
OpenAlexW2337594246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.